Drug Deliv Device Co’s Need New Strategies
October 28, 2009
This morning, my client Scientia Advisors released a global market review of the parenteral drug delivery device market–that is, devices that penetrate the skin to get medication into the bloodstream or specific tissue.
The main message is that companies will need to rethink their strategies as new therapies and decentralization, in which patients manage their own care, become more prevalent.
The study reviewed the growing market for parenteral technologies such as infusion, injection, catheters and implants that penetrate patients’ skin so that medication can be released into the bloodstream or local tissue.
Based on intensive primary and secondary research and proprietary analytic techniques, Scientia projects market growth of 7%, from $11.8B in 2007 to 16.7B in 2012. Growth in the parenteral market will be driven primarily by the increasing use of biological drugs such as insulin and monoclonal antibodies, which must be delivered through the skin. (If taken orally, they are digested by the gut and rendered ineffective).
While established markets (hospitals, clinics, laboratories, ambulances and the like) are sizable, the segment’s greatest growth will come as individual consumers increasingly manage chronic diseases—such as diabetes—on their own.
Companies would do well to focus on unmet needs for absolute sterility in the production and testing processes, on new formulations for pain-free injections, and on needle-free systems.
The review is available for download from Scientia’s Web site at www.scientiaadv.com.
Scientia Advisors, based in Cambridge, MA and Palo Alto, CA, is a global management consulting firm specializing in growth strategies for health care and the life sciences.
Blog.harriscom.com is published by the Harris Communications Group, a marketing communications and public relations firm in Cambridge, MA. We also publish the New Cambridge Observer.
Scientia Advisors Review: Life Science Tools industry
October 21, 2009
Scientia Advisors, my client, today released a comprehensive review of the Life Science Tools Industry.
Among the key points:
- It’s a complex arena, likely to remain largely in the US for the next few years, despite intense growth in the Asia-Pacific Region.
- The industry is fragmented despite dominance by just a handful of companies. Leading companies face competition as smaller companies consolidate.
- Scientia projects combined annual growth of eight per cent through 2012 and beyond.
- Growth is expected for cell-based assays and cell-isolation technologies; live cell analysis; cell-based assays for drug discovery research and development; kinases, RNAI and biomarker research, and cell preparation and manipulation.
The review is available for download from Scientia’s Web site at www.scientiaadv.com.
–Anita M. Harris
HarrisComBlog is a publication of the Harris Communications Group of Cambridge, MA. We also publish New Cambridge Observer.
My client, Scientia Advisors, says that diabetes care is undergoing a paradigm shift in which insulin is being prescribed earlier, for more conditions, in order to delay the onset of full-blown disease. In a study released today, the global management consulting firm finds that as more drugs go generic, companies offering newer, more expensive drugs will face resistance in markets most constrained by economics.
Harry Glorikian, Scientia Advisors’ managing partner, said: “While there are exciting developments in the non-insulin oral drug categories, the makers of these newer medications would be wise to stay attuned to how to best position their products—especially when marketing in emerging economies, which are extremely sensitive to costs.”
Scientia Advisors is a global management consulting firm specializing in growth strategies for major and emerging companies.
Glorikian said: “We expect that as more drugs become available in generic form, incretin mimetics (which increase insulin secretion) and insulins will generate an increasing share of the revenues. Therapies with benefits beyond glucose management (such as delaying the onset of diabetes or treating co-morbid conditions) will be used earlier in treatment. For a variety of reasons, “
The study outlines basic scientific facts about diabetes, diabetes markets in different parts of the world, and mechanisms of action for various diabetes medications.
It predicts growth and revenue share for individual drugs and describes the ways in which “players” and a changing treatment paradigm are affected by traditional, emerging and future drugs and technologies. The study also analyzes how alternative delivery methods (needle-free injection; intranasal, inhaled, dermal, buccal, rectal and new oral methods) will impact insulin usage.
The study, funded by Scientia itself, is based on extensive primary and secondary research and proprietary analytic methods. It’s available for download from Scientia’s Web site at www.scientiaadv.com.
—Anita M. Harris
HarrisComBlog is a publication of the Harris Communications Group of Cambridge, MA. We also publish New Cambridge Observer.
Scientia Advisors: New dynamic priming vaccine market growth
October 6, 2009
My client, Scientia Advisors, has posted a new study of the changing vaccine market dynamics on its Website at www.scientiaadv.com.
Through in-depth primary and secondary research, Scientia found that technological breakthroughs, national immunization programs and emerging vaccines for treating, rather than preventing, disease are priming the global vaccine market for growth–and that novel vaccine design and delivery methods are changing vaccine industry dynamics.
According to Scientia Managing Partner Harry Glorikian, “Large pharmaceutical companies, which today dominate 90 per cent of the current market, should expect increased competition as more small biotechnology companies enter the global marketplace.
“Vaccine-related companies of every size must understand varying government and global policies, price-setting, and manufacturing standards and should be prepared for sensitive economies of scale.”
The study describes the players and prospects for a variety of prophylactic and therapeutic vaccines; the status of global initiatives to develop vaccines to combat the world’s deadliest diseases; and regulatory and reimbursement trends in North and South America, Europe and Asia.
It’s available for download from Scientia’s Web site at www.scientiaadv.com.
Scientia Advisors, based in Cambridge, MA, and Palo Alto, CA, is a global management consulting firm specializing in growth strategies for major and emerging companies in health care and the life sciences, worldwide.
Anita M. Harris
President, Harris Communications Group
Cambridge, MA
HarrisComBlog is a publication of the Harris Communications Group of Cambridge, MA. We also public New Cambridge Observer.
